Esperion Therapeutics (ESPR) Convertible Debt (2012 - 2026)

Esperion Therapeutics' Convertible Debt history runs 8 years deep, the most recent figure standing at $97.4 million for Q1 2026.

• Quarterly Convertible Debt rose 0.54% year-over-year to $97.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $97.4 million (up 0.54% YoY) and the FY2025 annual result came in at $97.3 million, up 0.53% from the prior year.
• Convertible Debt was $97.4 million for Q1 2026 at Esperion Therapeutics, roughly flat from $97.3 million in the prior quarter.
• Across five years, Convertible Debt topped out at $262.9 million in Q3 2024 and bottomed at $96.7 million in Q4 2024.
• A 5-year average of $203.0 million and a median of $259.5 million in 2022 frame the typical range for Convertible Debt.
• Annual changes were most pronounced in 2024 — Convertible Debt increased 0.67% — and 2025, when it plunged 63.06%.
• Esperion Therapeutics' Convertible Debt stood at $259.9 million in 2022, then advanced by 0.65% to $261.6 million in 2023, then plunged by 63.02% to $96.7 million in 2024, then gained by 0.53% to $97.3 million in 2025, then climbed by 0.14% to $97.4 million in 2026.
• Business Quant data shows ESPR's Convertible Debt at $97.4 million in Q1 2026, $97.3 million in Q4 2025, and $97.1 million in Q3 2025.